Physician profile
Stephen Schwartz
NPI 1326056854
$762.83
in general payments reported to CMS, 2019-2025
12 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $20.47 · 2021: $36.60 · 2022: $73.94 · 2023: $197 · 2024: $101 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $405.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $199.24 | 2019-2024 | Eylea, Eylea Hd |
| Abbvie INC. | $196.42 | 2019-2023 | Ozurdex, Botox |
| Astellas Pharma US INC | $78.38 | 2025 | Izervay |
| Genentech USA, INC. | $67.07 | 2021-2023 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $48.63 | 2022-2024 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.14 | 2019 | |
| Aerie Pharmaceuticals, INC. | $31.97 | 2019 | |
| Harrow Eye, LLC | $29.14 | 2025 | Triesence |
| Mallinckrodt Hospital Products INC. | $19.76 | 2023 | Acthar |
| Oyster Point Pharma, INC. | $16.42 | 2022 | |
| Alcon Vision LLC | $16.27 | 2022 | |
| Halozyme INC | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.